Lu Hongbo's Form 4 filing
Zenas BioPharma, Inc. (ZBIO) · filed Oct 9, 2025
- Accession no.
- 0000919574-25-006031
- Filed
- Oct 9, 2025
- Trade date
- Sep 13, 2024-Oct 7, 2025
- Filing delay
- 391 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $6.00M. It was filed 391 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lu HongboCIK 0001767584 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | Common Stock | PPurchaseAcquired | +58,823 | $17.00 | +$999,991 | 58,823 | Indirect | |
| Oct 7, 2025 | Common Stock | PPurchaseAcquired | +263,160 | $19.00 | +$5,000,040 | 321,983 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.